Cargando…
PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy
Several clinical studies demonstrate that there exist other immune checkpoints overexpressed in some PD-1 inhibitor-resistant tumor patients. Among them, Lymphocyte-activation gene 3 (LAG-3) is one of the important immune checkpoint molecules and has been clinically demonstrated to have synergistic...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742559/ https://www.ncbi.nlm.nih.gov/pubmed/36518768 http://dx.doi.org/10.3389/fimmu.2022.1047610 |